People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses

作者：Hope R. Lapointe, Francis Mwimanzi, Peter K. Cheung, Yurou Sang, Fatima Yaseen, Gisele Umviligihozo, Rebecca Kalikawe, Sarah Speckmaier, Nadia Moran-Garcia, Sneha Datwani, Maggie C. Duncan, Olga Agafitei, Siobhan Ennis, Landon Young, Hesham Ali, Bruce Ganase, F. Harrison Omondi, Winnie Dong, Junine Toy, Paul Sereda, Laura Burns, Cecilia T. Costiniuk, Curtis Cooper, Aslam H. Anis, Victor C. M. Leung, Daniel T. Holmes, Mari L. DeMarco, Janet Simons, Malcolm Hedgcock, Natalie Prystajecky, Christopher F. Lowe, Ralph Pantophlet, Marc G. Romney, Rolando Barrios, Silvia Guillemi, Chanson J. Brumme, Julio Montaner, Mark Hull, Marianne Harris, Masahiro Niikura, Mark A. Brockman, Zabrina L. Brumme · 发表于：medRxiv · 年份：2022 · DOI：10.1101/2022.03.22.22272793 · 被引用次数：20 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、Immune responses and vaccinations

Background: Longer-term humoral responses to two-dose COVID-19 vaccines remain incompletely characterized in people living with HIV (PLWH), as do initial responses to a third dose. Methods: We measured antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement and viral neutralization against wild-type and Omicron strains up to six months following two-dose vaccination, and one month following the third dose, in 99 PLWH receiving suppressive antiretroviral therapy, and 152 controls. Results: Though humoral responses naturally decline following two-dose vaccination, we found no evidence of lower antibody concentrations nor faster rates of antibody decline in PLWH compared to controls after accounting for sociodemographic, health and vaccine-related factors. We also found no evidence of poorer viral neutralization in PLWH after two doses, nor evidence that a low nadir CD4+ T-cell count compromised responses. Post-third-dose humoral responses substantially exceeded post-second-dose levels, though anti-Omicron responses were consistently weaker than against wild-type.Nevertheless, post-third-dose responses in PLWH were comparable to or higher than controls. An mRNA-1273 third dose was the strongest consistent correlate of higher post-third-dose responses. Conclusion: PLWH receiving suppressive antiretroviral therapy mount strong antibody responses after two- and three-dose COVID-19 vaccination. Results underscore the immune benefits of third doses ...